or a pharmaceutically acceptable salt thereof, wherein

A is C_5 alkyl, C_6 alkyl, C_5 alkenyl, C_6 alkenyl, $C(O)-(CH_2)_n-CH_3$ or $CH(OH)-(CH_2)_n-CH_3$ wherein n is 3 or 4;

R_1 is H, F or OH;

R_2 is C_5 alkyl, C_6 alkyl, C_5 alkenyl, C_6 alkenyl, $C(O)-(CH_2)_n-CH_3$ or $CH(OH)-(CH_2)_n-CH_3$ wherein n is 3 or 4;

R_3 is H, F, OH or CH_2Ph;

R_4 is H, F or OH;

Q is

1) $(CH_2)_mC(O)OH$ wherein m is 1 or 2,

2) $CH(CH_3)C(O)OH$,

3) $C(CH_3)_2C(O)OH$,

4) $CH(F)-C(O)OH$,

5) $CF_2-C(O)OH$, or

6) $C(O)-C(O)OH$;

in the manufacture of a medicament for reducing collagen type 1 production in cells, wherein said compound is contacted with the cells.

7. Use of a therapeutically effective amount of a compound as defined in any one of claims 1 to 5 in the manufacture of a medicament for reducing collagen type 1 production in cells, wherein said compound is contacted with the cells.

8. Use of a therapeutically effective amount of a compound represented by the formula:

9. Use of a therapeutically effective amount of a compound as defined in any one of claims 1 to 5; in the manufacture of a medicament for preventing and/or slowing progression of and/or treating fibrosis in a subject in need thereof.

10. The use of claim 8 or 9, wherein the subject has a fibrotic disease that is selected from the group consisting of pulmonary fibrosis, liver fibrosis, skin fibrosis, renal fibrosis, pancreas fibrosis, systemic sclerosis, cardiac fibrosis and macular degeneration.

11. The use of claim 9 or 10, wherein the therapeutically effective amount is between about 1 to about 50 mg/kg, the compound is to be administered orally, and the subject is human.

12. The use of claim 11, wherein the therapeutically effective amount is between about 1 to about 20 mg/kg.

13. The use according to claim 10, wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis, sarcoidosis, cystic fibrosis, familial pulmonary fibrosis, silicosis, asbestosis, coal worker's pneumoconiosis, carbon pneumoconiosis, hypersensitivity pneumonitides, pulmonary fibrosis caused by inhalation of inorganic dust, pulmonary fibrosis caused by an infectious agent, pulmonary fibrosis caused by inhalation of noxious gases, aerosols, chemical dusts, fumes or vapors, drug-induced interstitial lung disease, pulmonary hypertension or chronic obstructive pulmonary disease.

14. The use according to claim 10, wherein the liver fibrosis is resulting from a chronic liver disease, hepatitis B virus infection, hepatitis C virus infection, hepatitis D virus infection, schistosomiasis, alcoholic liver disease or non-alcoholic steatohepatitis, obesity, diabetes, protein malnutrition, coronary artery disease, auto-immune hepatitis, cystic fibrosis, alpha-1-antitrypsin deficiency, primary biliary cirrhosis, drug reaction and exposure to toxins.

15. The use according to claim 10, wherein the skin fibrosis is scarring, hypertrophic scarring, keloid scarring, dermal fibrotic disorder, wound healing, delayed wound healing, psoriasis or scleroderma.

16. The use of claim 15, wherein said scarring derives from a burn, a trauma, a surgical injury, a radiation or an ulcer.

17. The use of claim 16, wherein said ulcer is diabetic foot ulcer, venous leg ulcer or pressure ulcer.

18. The use according to claim 10, wherein the kidney fibrosis is resulting from dialysis following kidney failure, catheter placement, a nephropathy, glomerulosclerosis, glomerulonephritis, chronic renal insufficiency, acute kidney injury, chronic kidney diseases, end stage renal disease or renal failure.

19. Use of a therapeutically effective amount of a compound, represented by the formula:



or a pharmaceutically acceptable salt thereof, wherein

A is C_5 alkyl, C_6 alkyl, C_5 alkenyl, C_6 alkenyl, $C(O)-(CH_2)_n-CH_3$ or $CH(OH)-(CH_2)_n-CH_3$ wherein n is 3 or 4;

R_1 is H, F or OH;

R_2 is C_5 alkyl, C_6 alkyl, C_5 alkenyl, C_6 alkenyl, $C(O)-(CH_2)_n-CH_3$ or $CH(OH)-(CH_2)_n-CH_3$ wherein n is 3 or 4;

R_3 is H, F, OH or CH_2Ph;

R_4 is H, F or OH;

Q is

1) $(CH_2)_mC(O)OH$ wherein m is 1 or 2,

2) $CH(CH_3)C(O)OH$,

3) $C(CH_3)_2C(O)OH$,

4) CH(F)-C(O)OH,

5) CF_2-C(O)OH, or

6) C(O)-C(O)OH;

in the manufacture of a medicament for antagonizing collagen type 1 secretion or collagen type 1 deposition in an organ of a mammal; and wherein the organ is lung, liver, kidney, pancreas, skin or heart.

20. Use of a therapeutically effective amount of a compound as defined in any one of claims 1 to 5, in the manufacture of a medicament for antagonizing collagen type 1 secretion or collagen type 1 deposition in an organ of a mammal, wherein the organ is lung, liver, kidney, pancreas, skin or heart.

21. The use according to any one of claims 6 to 20, wherein the compound is to be administered in combination with a therapeutically effective amount of second compound, the second compound is an immunosuppressive drug, an anti-inflammatory drug, a cytokine, a monoclonal antibody, a multiple receptor tyrosine kinase inhibitor, an antioxidant, an enzyme inhibitor, an integrin inhibitor, an hypertensive inhibitor, a lipid receptor modulator or an anti-diabetic drug.